Abstract
In countries where hepatitis B is endemic, early infant immunization has also been recommended. Since the coverage in Indonesia, a combination of HB with DTP was considered to be a good way to increase the coverage of HB immunization. In Indonesia, the Lombok study Haemophylus influenzae. 4 The limited immunogenicity of the polysacchain infants and young children led to the development the process of chemically bonding a polysaccharide, a somewhat ineffective antigen, to a protein carrier, a more effective antigen. This process changes the polysaccharide from a T-independent to a T-dependent antigen and greatly improves immunogenicity, particularly in young children. 5 vaccine is one such vaccine that can be used as part of EPI. It has dramatically reduced the incidence of Hib meningitis. This vaccine is given in a schedule of three doses during infancy, together with DPT, with or 3, 4 The aim of this trial was to assess the safety and imformulated by Bio Farma. health center for the first three days after the first immunization dose for adverse events. The reactions cards collected and confirmed by the investigators at --nus were evaluated using the enzyme-linked immunowere tested using a microagglutination method. All four methods had been validated and were done at the Clinical Trial Department of Bio Farma after blinding procedure. Anti-HB antibodies were tested using a kit from Abbott in a commercial laboratory which had been audited by Quality Assurance from Bio Farma. The original identity of the samples was concealed to ensure unbiased antibody testing. diphtheria, tetanus, pertussis, and hepatitis B were calculated in percentages. Protective levels of Hib For tetanus Seroconversion rates are calculated by the percentage fold antibody increase after immunization. Geometric mean titers prior to immunization were compared to those after immunization.
Methods

Results
vaccine, and met the protocol criteria.
Adverse events reported after immunization are summarized in Table 1 with immediate local reactions or systemic events -sented with immediate local reactions or systemic -tion and no serious adverse events were observed during the study.
After the 3 rd were considered to be protected against Hib, as the post-immunization ( Table 2 ).
The proportions of infants who had postimmunization anti-diphtheria titers of mL post-immunization. The proportions of infants who had post-immunization anti-tetanus titers of respectively. The GMT of anti-tetanus antibodies infants underwent an anti-diphtheria transition from seronegative to seropositive (Table 3) . increased antibody titers (Table 4) . The proportion of infants with anti-hepatitis B to seropositive (Table 5) . post-booster seroconversion rates). n.a: percentage of infants presenting with anti-tetanus transition of seronegative to seropositive is not applicable, since all the subjects were protected before immunization 
Discussion
The availability of combined vaccines containing ideally all, diseases for which universal immunization is recommended in infancy would simplify the implementation, increase the acceptance, reduce the global cost of immunization programs, and improve disease control, while offering the possibility of disease elimination or even pathogen eradication. Vaccine development proceeds through discovery, process engineering, toxicology, and animal studies to human phase I, II, and III trials. The human trials initially focus on safety, involving small groups of people populations (persons close to the age and other to determine both safety and the stimulation of an target populations to establish whether a vaccine in our phase I trial. All participants were intensively examined at the primary health care center during the I study demonstrated good safety and immunogenicity There were no serious local or systemic reactions in this study. All observed reactions were slight, the administration of the vaccine and resolved without medical intervention. The anti-PRP antibody GMT significantly increased after the 3 rd mL , compared to the concentrations found in prevaccination sera, and most infants had a 4-fold-orseroprotective antibodies against tetanus, diphtheria, and hepatitis B. We observed good immunogenicity and reactogenicity profiles for the new combined Combination vaccines have numerous advanincreased compliance, better coverage, and simplified logistics. They also result in substantial reductions in program costs, since the indirect costs of immunizing a child (e.g., logistics, materials involved, payment of combination vaccine for primary and booster vaccination study of infants in Latin America showed that both vaccination regimens elicited excellent immune seroprotective anti-PRP antibody concentrations of was given in one shot immunization in the left thigh shots at the different thigh (e.e combined DTPw-HB was not inferior to licensed vaccines in terms of seroprotection, seropositivity, and vaccine response rates for all component antigens. Persistence of antibodies against all study vaccine antigens up to the time of booster vaccination was comparable between groups, and a marked increase of all antibody concentrations was observed after the booster dose. Both vaccine regimens were similar in terms of their overall reactogenicity profiles. pathogens and will ease the implementation of global pediatric immunization programs, with a minimum coverage.
In conclusion, the excellent safety profile and antibody responses in the infants observed during this study encourage us to proceed to further clinical evaluations in phase II.
